Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 12, 2018

View Archived Issues

Probiotics: not all that

Overcoming aggravations in studying aggregation

Studying bacterial autoimmunity yields new CRISPR/Cas inhibitors

Getting to the bottom of complex genomics

New DPP IV inhibitor adapentpronitrile protects against diabetic neuronal injury

Researchers develop new rat model of post-traumatic joint stiffness of the knee

Researchers identify novel class of potent gamma-secretase modulators

Cyclacel initiates phase Ib/II study of sapacitabine with olaparib in BRCA-mutant breast cancer

Five Prime advances FIGHT study of bemarituzumab in gastric and gastroesophageal cancer

European Commission approves Keytruda with pemetrexed and chemotherapy for first-line NSCLC

Regulation, edification, sedation: 2018 Laskers honor research on complexity beyond DNA

Researchers present first-in-human data for AT-04A

Trevena patents new delta-opioid receptor modulators

Phase III study of Zerbaxa in HABP and VABP meets primary endpoints

SuPAR predicts chronic kidney disease progression in Black Americans

RQx Pharmaceuticals and Genentech present antibacterial compounds

Innate Tumor Immunity synthesizes new NLRP3 agonists for cancer

Prelude Therapeutics identifies new PRMT5 inhibitors

Dual sHE inhibitor/PPAR-gamma agonist shows benefits to treat metabolic syndrome and diabetes in rat

Janssen Pharmaceutica presents OGA inhibitors

Innate Pharma initiates phase I study of IPH-5401 with durvalumab in solid tumors

FINCH 2 study of filgotinib in rheumatoid arthritis meets primary endpoint

European Commission approves Veyvondi for adults with von Willebrand disease

Vital Therapies ceases development of ELAD cell-based therapy

DSMB recommends continuation of EPITOPE study of Viaskin Peanut in toddlers

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...